JAMIE WILLIAMS: Open Payments
NPI 1477801918 · ATHENS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,977 in 105 payments from 17 companies in 2025. Trend: 2023 $1,530 · 2024 $1,433 · 2025 $1,977
Food & beverage: $1,878Education: $99
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $499 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 19 | $267 |
| Janssen Biotech, Inc. | 9 | $249 |
| GENZYME CORPORATION | 7 | $163 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $143 |
| Regeneron Healthcare Solutions, Inc. | 5 | $111 |
| Lilly USA, LLC | 6 | $101 |
| QOL Medical, LLC | 4 | $99 |
| Ipsen Biopharmaceuticals, Inc | 3 | $66 |
| PFIZER INC. | 3 | $54 |
Products named: DUPIXENT, XIFAXAN, TREMFYA, RINVOQ, SKYRIZI, LINZESS, ENTYVIO, OMVOH.
Industry payments across GA — which companies pay providers there.
